294 related articles for article (PubMed ID: 16267739)
1. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
[TBL] [Abstract][Full Text] [Related]
2. Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Mathiesen S; Justesen US; Von Lüttichau HR; Hansen AB
Scand J Infect Dis; 2006; 38(8):733-5. PubMed ID: 16857630
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
[TBL] [Abstract][Full Text] [Related]
6. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
[TBL] [Abstract][Full Text] [Related]
8. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Friedland G; Khoo S; Jack C; Lalloo U
J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.
Read TR; Carey D; Mallon P; Mijch A; Goodall R; Hudson F; Wand H; Emery S
AIDS; 2009 Oct; 23(16):2222-3. PubMed ID: 19773634
[TBL] [Abstract][Full Text] [Related]
10. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
Almond LM; Hoggard PG; Edirisinghe D; Khoo SH; Back DJ
J Antimicrob Chemother; 2005 Oct; 56(4):738-44. PubMed ID: 16141277
[TBL] [Abstract][Full Text] [Related]
11. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
[TBL] [Abstract][Full Text] [Related]
12. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
[TBL] [Abstract][Full Text] [Related]
13. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
Fumaz CR; Muñoz-Moreno JA; Moltó J; Negredo E; Ferrer MJ; Sirera G; Pérez-Alvarez N; Gómez G; Burger D; Clotet B
J Acquir Immune Defic Syndr; 2005 Apr; 38(5):560-5. PubMed ID: 15793366
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
Haas DW; Ribaudo HJ; Kim RB; Tierney C; Wilkinson GR; Gulick RM; Clifford DB; Hulgan T; Marzolini C; Acosta EP
AIDS; 2004 Dec; 18(18):2391-400. PubMed ID: 15622315
[TBL] [Abstract][Full Text] [Related]
15. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.
Bickel M; Stephan C; Rottmann C; Carlebach A; Haberl A; Kurowski M; Staszewski S
Scand J Infect Dis; 2005; 37(6-7):520-2. PubMed ID: 16012018
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals.
Scourfield A; Zheng J; Chinthapalli S; Waters L; Martin T; Mandalia S; Nelson M
AIDS; 2012 Jul; 26(11):1399-401. PubMed ID: 22441251
[TBL] [Abstract][Full Text] [Related]
17. Efavirenz: enhancing the gold standard.
Arribas JR
Int J STD AIDS; 2003 Oct; 14 Suppl 1():6-14. PubMed ID: 14617398
[TBL] [Abstract][Full Text] [Related]
18. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
[TBL] [Abstract][Full Text] [Related]
19. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
[TBL] [Abstract][Full Text] [Related]
20. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
